预测天然产物的价值：抗结核药物空间的探索。
Predicting natural product value, an exploration of anti-TB drug space.
机构信息
Eskitis Institute for Drug Discovery, Griffith University, Brisbane, Queensland, Australia.
出版信息
Nat Prod Rep. 2014 Aug;31(8):990-8. doi: 10.1039/c4np00021h.
Covering: January 1990 to December 2012. Mycobacterium tuberculosis (Mtb) still remains a deadly pathogen two decades after the announcement of tuberculosis (TB) as a global health emergency by the World Health Organization. In last few years new drug combinations have shown promising potential to significantly shorten TB treatment times. However there are very few new chemical entities being developed to treat this global threat. From January 1990 to December 2012, 949 anti-mycobacterium natural products were reported in the literature. Here we present a perspective based on an analysis of the drug-like properties of the reported anti-mycobacterium natural products in order to assess drug potential.
涵盖时间
1990 年 1 月至 2012 年 12 月。在世界卫生组织宣布结核病（TB）为全球卫生紧急事件二十年后，结核分枝杆菌（Mtb）仍然是一种致命的病原体。在过去的几年中，新的药物组合已显示出有希望的潜力，可以显著缩短结核病的治疗时间。然而，用于治疗这一全球威胁的新化学实体却寥寥无几。从 1990 年 1 月至 2012 年 12 月，文献中报道了 949 种抗分枝杆菌天然产物。在这里，我们基于对报道的抗分枝杆菌天然产物的药物特性进行分析，提出了一种观点，以评估药物潜力。
Zotero 插件